the aid library

LIST OPTIONS

Filter

1986

Countdown to 2023: WHO report on global trans-fat elimination 2022 WHO

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are responding to the World Health Organization (WHO) call t... more

Asia Pacific Health Security Action Framework

World Health Organization WHO (2024) C_WHO

Public health emergencies, including pandemics, highlight the need for health systems and services that are prepared, resilient and ready to respond to health security threats. Endorsed by Member States in 2023, the Asia Pacific Health Security Action Framework (‎APHSAF)‎ is designed to engage m... more

Download (230)

View PDF (270)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (194)

View PDF (236)

Setting Up a Cancer Centre: A WHO–IAEA Framework

World Health Organization WHO; International Atomic Energy Agency IAEA (1989) C1

Cancer centres are a major resource in ensuring a comprehensive approach to cancer treatment and its planning. As part of a new roadmap developed by WHO and IAEA to help countries design national cancer control programmes, this publication proposes a framework to develop a cancer centre and/or to st... more

Download (134)

View PDF (194)

Global roadmap for research and development of tuberculosis vaccines

European & Developing Countries Clinical Trials Partnership EDCTTP; Amterdam Institute for Global health & Development aighd (2021) C1

The roadmap describes the actions needed to achieve the three development goals for TB vaccines set by the WHO: 1. A safe, effective and affordable TB vaccine for adolescents and adults. 2. An affordable TB vaccine for neonates and infants with improved safety and efficacy. 3. A therapeutic v... more

Download (169)

View PDF (223)

Guideline for the Treatment of Leishmaniasis in the Americas
recommended

World Health Organization WHO (2022) C_WHO

2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ... more

Download (287)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Humanitarian assistance and protection for people on the move

The International Federation of Red Cross and Red Crescent Societies IFRC (2021) C1

People on the move – migrants, refugees, asylum seekers and other displaced populations – face extraordinary risks to their lives, safety, dignity, human rights and well-being. In part this is connected to the core reasons that lead to migration and displacement, ranging from violence, persec... more

Download (463)

View PDF (532)

DRC: Cadre de Gestion environnementale et sociale (CGES)

Ministère de la Santé Publique, Republique Démocratique du Congo (2016) C1

Download (327)

View PDF (324)

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers, second edition

World Health Organization WHO (2021) C_WHO

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers, second edition: web annex A: protocol for evaluating minimum package of care of morbidity management and disability prevention for lymphoedema management in designated health facilit... more

Download (133)

View PDF (152)

Haiti: What did we learn? The Shelter Response and Housing Recovery in the First Two Years after the 2010 Haiti Earthquake

GFDRR Habitat for Humanity IFRC; et al. (2016) CC

This report is not a formal evaluation, but rather a synthesis of the experiences, observations, and recommendations of a large group of experienced post-disaster shelter and recovery experts gathered from interviews, surveys, and direct discussions, and information derived from a desk review of the... more

External Link

NATIONAL MEDICAL STANDARD FOR REPRODUCTIVE HEALTH Vol I

Government of Nepal Ministry of Health and Population Family Health Division (2010)

4th Edition

Download (141)

View PDF (174)

A UN framework for the immediate socio-economic response to COVID-19

United Nations (2020) C2

The “United Nations Framework for the immediate socio-economic response to COVID-19: Shared responsibility, global solidarity and urgent action for people in need” calls for protecting jobs, businesses and livelihoods to set in motion a safe recovery of societies and economies as soon as possibl... more

External Link

Bacille Calmette–Guérin vaccination: the current situation in Europe

M. Dara, C. D. Acosta, V. Rusovich, et al. The European Respiratory Journal (2014) C2

Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413

Download (421)

View PDF (670)

Improving payment mechanisms to support a new delivery model for TB care in Romania

L. Imre, A. Lourenço, N. Ahamed, et al. World Health Organization Europe (2017) C_WHO

Guidelines for the implementation of non-pharmaceutical interventions against COVID-19

European Centre for Disease Prevention and Control ECDC (2016) C1

Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk of severe COVID-19, NPI are the most effective public health interventions against... more

Download (170)

View PDF (277)

Prevention of Depression and Promotion of Resilience. Consensus Paper

Pim Cuijpers, Laura Shields-Zeeman, Bethany Hipple Walters, Ionela Petrea European Union EU (2016) CC

EU Compass for Action on Mental Health and Well-being

Download (488)

View PDF (893)

Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

European Centre for Disease Prevention and Control (2018) C1

The main objective of this guidance is to provide scientific advice, based on an evidence-based assessment of targeted public health interventions, to facilitate effective screening and vaccination for priority infectious diseases among newly arrived migrant populations to the EU/EEA. It is intended... more

Download (215)

View PDF (517)

Systematic review on the diagnosis, treatment, care and prevention of tuberculosis in prison settings

European Centre for Disease Prevention and Control (2017) C_CDC

Scientific advice Prevention and control of communicable diseases in prison settings.

Download (119)

View PDF (368)

Доклад ВОЗ о глобальной табачной эпидемии, 2009 год- Создание среды, свободной от табачного дыма

World Health Organization (2010) C_WHO

Доклад ВОЗ о глобальной табачной эпидемии, 2009 год: Создание среды, свободной от табачного дыма, – второй из серии докладов ВОЗ, в которых определяется состояние таб... more

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Guideline for the Treatment of Leishmaniasis in the Americas recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Guideline for the Treatment of Leishmaniasis in the Americas
recommended